HWAIF Stock Chart & Stats
$0.47
$0.01(2.41%)
At close: 4:00 PM EDT
$0.47
$0.01(2.41%)
Day’s Range― - ―
52-Week Range$0.39 - $1.23
Previous CloseN/A
Volume18.56K
Average Volume (3M)255.06K
Market Cap
$154.88M
Enterprise Value$294.39
Total Cash (Recent Filing)$21.95M
Total Debt (Recent Filing)$86.73M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding303,547,420
10 Day Avg. Volume282,859
30 Day Avg. Volume255,059
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.70
Price to Sales (P/S)2.03
P/FCF Ratio-10.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.61Price Target Upside243.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$98.02M
Bulls Say, Bears Say
Bulls Say
Platform Scale & Data MoatThe company's extensive dataset and clinical footprint create durable network effects and high switching costs. Broad provider coverage plus DARWEN clinical validations strengthen product defensibility, accelerate model improvement, and support long‑term customer retention and regulatory credibility.
Revenue & Adjusted EBITDA TrajectoryMaterial H1 top‑line growth and a sharp adjusted EBITDA improvement demonstrate the company can scale revenue and begin converting scale into operating leverage. If sustained, this trajectory supports reinvestment into sales and product while reducing reliance on dilutive funding over time.
Improved Cash Flow & Balance SheetPositive H1 operating cash flow and reduced leverage increase financial flexibility and covenant resilience. Better cash generation and a strengthened balance sheet lower near‑term refinancing risk and provide capacity to fund integration, product development, and enterprise sales investments.
Bears Say
Persistent Cash BurnTrailing‑twelve‑month negative operating and free cash flows indicate the company still burns cash and remains reliant on external funding or balance‑sheet capacity. Continued losses erode equity and heighten execution risk until consistent positive FCF and margins are achieved.
Elongated Enterprise Sales CyclesLonger 6–9 month sales cycles slow conversion of pilots to enterprise licenses, increasing cash conversion times and customer acquisition costs. This structural cadence delay makes revenue and margin realization more variable and pushes material AI/Data Science growth into later periods.
Integration & Synergy Execution RiskPartial completion of synergies and a lengthy tech‑debt/R&D consolidation timeline mean promised margin expansion is contingent on execution. Delays or higher integration costs would compress expected margins and prolong the path to stable, enterprise‑grade recurring revenue.
HEALWELL AI News
HWAIF FAQ
What was HEALWELL AI’s price range in the past 12 months?
HEALWELL AI lowest stock price was $0.39 and its highest was $1.23 in the past 12 months.
What is HEALWELL AI’s market cap?
HEALWELL AI’s market cap is $154.88M.
When is HEALWELL AI’s upcoming earnings report date?
HEALWELL AI’s upcoming earnings report date is Nov 16, 2026 which is in 98 days.
How were HEALWELL AI’s earnings last quarter?
HEALWELL AI released its earnings results on Aug 07, 2026. The company reported $0.014 earnings per share for the quarter, beating the consensus estimate of -$0.018 by $0.032.
Is HEALWELL AI overvalued?
According to Wall Street analysts HEALWELL AI’s price is currently Undervalued.
Does HEALWELL AI pay dividends?
HEALWELL AI does not currently pay dividends.
What is HEALWELL AI’s EPS estimate?
HEALWELL AI’s EPS estimate is -0.02.
How many shares outstanding does HEALWELL AI have?
HEALWELL AI has 303,547,420 shares outstanding.
What happened to HEALWELL AI’s price movement after its last earnings report?
HEALWELL AI reported an EPS of $0.014 in its last earnings report, beating expectations of -$0.018. Following the earnings report the stock price went down -2.045%.
Which hedge fund is a major shareholder of HEALWELL AI?
Currently, no hedge funds are holding shares in HWAIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HEALWELL AI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.61 (243.04% Upside)
$1.61 (243.04% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.03%
Trailing 12-Months
Company Description
HEALWELL AI
Healwell AI Inc., a Toronto-based healthcare technology firm established in 2012, specializes in leveraging artificial intelligence and data science to advance preventative medical care. The company develops an AI-powered platform designed to assist healthcare providers with crucial decision-making. They maintain a significant strategic partnership with WELL Health Technologies Corp., focusing on accelerating the expansion and innovation of AI-driven healthcare solutions. Prior to its current name, adopted in October 2023, the organization was known as MCI Onehealth Technologies Inc.
HWAIF Stock 12 Month Forecast
Average Price Target
$1.61
▲(243.04% Upside)
Technical Analysis
Cardiocomm Solutions
―
Reliq Health Technologies
―
Leveljump Healthcare Corp.
―
Kovo HealthTech Corporation
―
Hydreight Technologies Inc
―
Ownership Overview
12.66% Insiders
<0.01% Other Institutional Investors
87.33% Public Companies and
Individual Investors